Treatment with Interferon-Alpha2a Alone or Interferon-Alpha2a plus Ribavirin in Patients with Chronic Hepatitis C Previously Treated with Interferon-Alpha2a
- 1 January 1999
- journal article
- clinical trial
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 34 (2) , 194-198
- https://doi.org/10.1080/00365529950173087
Abstract
Preliminary results from combination therapy with interferon-alpha and ribavirin (IFN/Rib) in patients with chronic hepatitis C have been promising, with up to 50% sustained hepatitis C virus (HCV) RNA response. The aim of this study was to investigate whether a sustained HCV RNA response could be obtained with combination therapy in patients who were non-responders or relapsers after IFN treatment. In a multicenter study we randomized 53 HCV RNA-positive patients into 2 treatment groups. They all had biopsy-confirmed chronic hepatitis C, and all were recruited from a previous IFN study: 26 were previous non-responders and 27 responders with relapse. Group A received interferon-alpha2a, 4.5 MIU thrice weekly for 6 months, and group B received ribavirin, 1000-1200 mg/day, in combination with the same dose of interferon-alpha2a for 6 months. Median Knodell index was 5.0 in both groups. Genotype 1 was found in 24 (45%), type 2 in 3 (6%), and type 3 in 26 (49%). Sustained clearance of HCV viremia 6 months after interferon-alpha2a treatment stop was obtained in 12 of 53 patients (23%): 6 of 27 in the IFN group (22%) and 6 of 26 (23%) in the IFN/Rib group (NS). Nine of 27 (33%) former responders with relapse, compared with 3 of 26 (12%) non-responders, obtained a sustained HCV RNA response (P = 0.054). In previous relapse patients sustained loss of viremia was more frequent in genotype 3 (50%) than in genotype 1 (11%) patients (P = 0.022). In a group of previous IFN-alpha2a-treated chronic HCV patients we obtained a similar sustained clearance of viremia when retreated either with IFN-alpha2a alone or with a combination of IFN-alpha2a and ribavirin for 6 months. Previous relapse patients with HCV genotype 3 obtained sustained loss of viremia significantly more often (50%) than type-patients (11%). Previous IFN responders with relapse responded better than previous non-responders.Keywords
This publication has 8 references indexed in Scilit:
- Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis CNew England Journal of Medicine, 1998
- Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: Meta-analysis of individual patient data from European centersJournal of Hepatology, 1997
- The Treatment of Chronic Viral HepatitisNew England Journal of Medicine, 1997
- Meta–Analysis of Interferon Randomized Trials in the Treatment of Viral Hepatitis C: Effects of Dose and DurationHepatology, 1996
- A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis CGastroenterology, 1994
- A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis CGastroenterology, 1993
- Ribavirin treatment for chronic hepatitis CThe Lancet, 1991
- Treatment of Chronic Hepatitis C with Recombinant Interferon AlfaNew England Journal of Medicine, 1989